Remotely Controlled Miniature Biological Robots Could Be Used for MIS and Detection of Disease Biomarkers
|
By LabMedica International staff writers Posted on 23 Jan 2023 |

A team of researchers has developed remotely controlled miniature biological robots that could find potential applications in medicine, such as minimum invasive surgery or detection of cancer within the human body.
The hybrid “eBiobots” are the first to combine soft materials, living muscle and microelectronics, according to researchers at the University of Illinois Urbana-Champaign (Champaign, IL, USA), Northwestern University (Evanston, IL, USA) and collaborating institutions. They have described their centimeter-scale biological machines in the journal Science Robotics.
Researchers at the University of Illinois Urbana-Champaign had earlier developed biobots, which are small biological robots powered by mouse muscle tissue grown on a soft 3D-printed polymer skeleton. In 2012, the team had demonstrated walking biobots. In 2016, they had also demonstrated light-activated biobots which provided the researchers with some control. However, the inability to deliver the light pulses to the biobots outside of a lab setting limited their practical applications. This time, researchers at Northwestern University helped integrate tiny wireless microelectronics and battery-free micro-LEDs, allowing them to remotely control the eBiobots.
With the aim of providing freedom of movement to the biobots in order to make them suitable for practical applications, the researchers focused on eliminating bulky batteries and tethering wires. The eBiobots use a receiver coil to harvest power and provide a regulated output voltage to power the micro-LEDs. The researchers are able to send a wireless signal to the eBiobots that prompts the LEDs to pulse. The LEDs stimulate the light-sensitive engineered muscle to contract, moving the polymer legs so that the machines can “walk.” The micro-LEDs are so targeted in a way that they can activate specific portions of muscle, making the eBiobot turn in the desired direction.
Using computational modeling, the researchers optimized the eBiobot design and integrated the components for robustness, speed and maneuverability. The iterative design and additive 3D printing of the scaffolds enabled rapid cycles of experiments and improvement in performance, according to the researchers. The design offers potential for future integration of additional microelectronics, such as chemical and biological sensors, or 3D-printed scaffold parts for functions like pushing or transporting things that the biobots can encounter. The integration of electronic sensors or biological neurons could allow the eBiobots to sense and respond to biomarkers for disease, among other possibilities.
“Integrating microelectronics allows the merger of the biological world and the electronics world, both with many advantages of their own, to now produce these electronic biobots and machines that could be useful for many medical, sensing and environmental applications in the future,” said study co-leader Rashid Bashir, an Illinois professor of bioengineering and dean of the Grainger College of Engineering.
“In developing a first-ever hybrid bioelectronic robot, we are opening the door for a new paradigm of applications for health care innovation, such as in-situ biopsies and analysis, minimum invasive surgery or even cancer detection within the human body,” said co-first author Zhengwei Li, an assistant professor of biomedical engineering at the University of Houston.
Related Links:
University of Illinois Urbana-Champaign
Northwestern University
Latest Technology News
- AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
- Agentic AI Platform Supports Genomic Decision-Making in Oncology
- Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
- Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
- AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
- AI Tool Automates Validation of Laboratory Software Configuration Changes
- Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
- Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
- Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
- New Platform Captures Extracellular Vesicles for Early Cancer Detection
- Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
- AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
- Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
- Noninvasive Sputum Test Detects Early Lung Cancer
- New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
- Rapid Biosensor Detects Drug Sensitivity in Breast Tumors
Channels
Clinical Chemistry
view channel
Simple Oral Swab Monitors Persistent Inflammation in Primary Ciliary Dyskinesia
Primary ciliary dyskinesia is a rare lung disease that affects about one in 7,500 to 10,000 live births worldwide. Symptoms can begin in the newborn period and progress to recurrent respiratory infections... Read more
Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features
Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read moreMolecular Diagnostics
view channel
New Blood Test Predicts Organ-Specific Disease and Mortality Years in Advance
Quantifying organ-specific aging remains a diagnostic challenge, even as age-related disorders drive morbidity and mortality worldwide. Chronological age poorly reflects the physiologic decline that predisposes... Read moreGenomic Assay Predicts Recurrence Risk in Noninvasive Breast Cancer
Ductal carcinoma in situ (DCIS) is a common noninvasive breast malignancy in which treatment decisions hinge on accurately estimating recurrence risk. Approximately 60,000 women are diagnosed each year... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Antibody Profiles Provide Clues to Long COVID Severity and Symptoms
Persistent symptoms after acute COVID-19 affect millions of people, causing fatigue, respiratory issues, and cognitive deficits that can be difficult to quantify with standard tests. Clinical teams lack... Read moreAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more
New Protein Targets Support Diagnostics for Louse-Borne Relapsing Fever
Louse-borne relapsing fever is a neglected infection caused by Borrelia recurrentis and spread by body lice, with untreated mortality reaching up to 20%. Recurrent febrile episodes complicate recognition... Read more
TORCH Infection Trends Point to Need for Tailored Screening in Pregnancy
Congenital TORCH infections can be asymptomatic during pregnancy yet cause stillbirth, birth defects, and lifelong disability in infants. Many regions still lack robust surveillance to guide testing and... Read more
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read morePathology
view channel
Stain-Free Imaging Platform Matches Standard Cancer Pathology
Histopathology underpins cancer diagnosis, but turnaround times and inter-laboratory variability can limit timely, consistent interpretation. Conventional staining relies on chemical dyes and multiple... Read more
New Companion Diagnostic Expands Precision Medicine in Prostate Cancer
Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read moreIndustry
view channel
Partnership Expands Ultrasensitive Blood-Based Diagnostics for Hematologic Malignancies
Predicta Biosciences (Cambridge, MA, USA) and CIMA LAB Diagnostics at Clínica Universidad de Navarra (Pamplona, Spain) have entered an agreement to provide a joint service that combines CIMA LAB’s flow... Read more








